JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shoker, B S
Right arrow Articles by Sloane, J P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shoker, B S
Right arrow Articles by Sloane, J P
J Clin Pathol 2000; 53:778-783
© 2000 Journal of Clinical Pathology

Abnormal regulation of the oestrogen receptor in benign breast lesions

B S Shoker1, C Jarvis1, R B Clarke2, E Anderson2, C Munro1, M P A Davies3, D R Sibson3, J P Sloane1

1 Department of Pathology, University of Liverpool, The Duncan Building, Daulby Street, Liverpool L69 3GA, UK
2 Clinical Research Department, Christie Hospital NHS Trust, Manchester M20 4BX, UK
3 JK Douglas Cancer Research Laboratory, Clatterbridge Hospital, Bebington, Wirral CH63 4JY, UK

Dr Shoker b.s.shoker@ Liverpool.ac.uk Background—In normal breast tissue the oestrogen receptor (ER) and the proliferation associated antigen Ki67 are negatively associated, indicating that ER+ cells are non-dividing, or that the receptor is downregulated as cells enter cycle. This relation is completely or partially lost in many ER+ breast cancers and in in situ proliferations associated with an increased cancer risk, where coexpression of the two markers is often found.

Aims—To determine whether similar changes can be identified in other risk associated breast lesions.

Patients/Methods—Paraffin wax blocks from 12 cases of lactational change, 21 apocrine metaplasias, 22 duct ectasias, 20 sclerosing adenosis, 20 fibroadenomas, 19 phyllodes tumours, 20 radial scars, 21 papillomas (15 solitary and six multiple), 15 gynaecomastias, and nine postmortem male breast tissues were retrieved. Immunohistochemistry was used to determine the expression of ER and dual labelling immunofluorescence was used to detect cells expressing both ER and Ki67.

Results—Increased numbers of ER+ cells were seen in sclerosing adenosis, radial scars, papillomas, fibroadenomas, and phyllodes tumours but not in apocrine cysts (where no ER+ cells were detected) or duct ectasia (where normal numbers were found). As in the normal breast, the proportion of ER+ cells increased with age in all lesions with the exception of fibroadenomas. Coexpression of ER and Ki67 was found in an increased proportion of cells of all risk associated lesions studied. ER+ cells were less likely to be dividing than ER- cells in all cases, although this was significant only for sclerosing adenosis. The data on sclerosing adenosis, radial scars, papillomas, and fibroadenomas are comparable with those reported previously in hyperplasia of usual type, whereas those in duct ectasia are similar to those of the normal breast. The findings in all lesions, however, differed from those in ductal carcinoma in situ, where proportions of ER+ and ER+/Ki67+ cells are higher and the relation between ER+ cell numbers and age is lost. Thus, the nature and degree of dysregulation of ER in benign breast lesions is broadly in accordance with the degree of risk of developing breast cancer with which they are associated. In gynaecomastia, the proportions of ER+ and ER+/Ki67+ cells were comparable with those seen in benign female breast lesions, but changes with age were not observed. However, the changes in gynaecomastia were similar to those seen in normal male breast.

Conclusion—These findings are in keeping with the contention that the dissociation of ER and Ki67 expression is a very early change in the pathway to many breast cancers. However, this change might only have preneoplastic importance in the hormonal milieu of the female breast.

Key Words: oestrogen receptor • proliferation • benign breast • precancerous breast




This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
S E Pinder and J S Reis-Filho
Non-operative breast pathology: columnar cell lesions
J. Clin. Pathol., December 1, 2007; 60(12): 1307 - 1312.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
S A Khan, D Bhandare, and R T Chatterton Jr
The local hormonal environment and related biomarkers in the normal breast
Endocr. Relat. Cancer, September 1, 2005; 12(3): 497 - 510.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
M. Fan, H. Nakshatri, and K. P. Nephew
Inhibiting Proteasomal Proteolysis Sustains Estrogen Receptor-{alpha} Activation
Mol. Endocrinol., November 1, 2004; 18(11): 2603 - 2615.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
H. K. Gill, O. B. Ioffe, and W. A. Berg
When Is a Diagnosis of Sclerosing Adenosis Acceptable at Core Biopsy?
Radiology, July 1, 2003; 228(1): 50 - 57.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2000 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.